The neuroprotective effect of immune serum of adeno-associated virus vaccine containing Aβ1-15 gene on amyloid toxicity

Annals of Indian Academy of Neurology
Ling-Yun LiuWen Li

Abstract

The aim of this study was to explore the effect of adeno-associated virus (AAV) serotype 2 vector vaccine containing amyloid-β peptide (Aβ) 1-15 gene fragment (AAV-Aβ15) immunized mice sera on counteracting Aβ1-42 peptide toxicity towards a primary culture cortical neurons. BALB/c mice were vaccinated via the intramuscular immunization route with AAV-Aβ15. The anti-Aβ antibody titer of immunized mice sera was quantified by sandwich Enzyme-Linked ImmunoSorbent Assay. The toxicity of Aβ1-42 peptide on neurons was assessed by morphology with an inverse microscopy and cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. AAV-Aβ15 could induce an Aβ-specific immunoglobulin G (IgG) humoral immune response in /c mice the anti-Aβ antibodies were detectable at 1 month after immunization, significantly increased at 2 and 4 months after immunization, and the immunized sera could attenuate cytotoxicity of Aβ1-42 peptide on primary culture cortical neurons. The immune serum of AAV-Aβ15 could play a neuroprotective effect against Aβ1-42 peptide toxicity, which would be beneficial for Alzheimer's disease patients.

References

Sep 22, 1999·Gene Therapy·N ChirmuleJ Wilson
Feb 8, 2003·DNA and Cell Biology·Chooi May LaiP Elizabeth Rakoczy
Nov 1, 2003·Science·Alon Monsonego, Howard L Weiner
Feb 15, 2005·Neurobiology of Aging·Valeria GeylisMichael Steinitz
May 5, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Marcel MaierCynthia A Lemere
Mar 8, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Akihiro MouriToshitaka Nabeshima
May 8, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alice ToromanoffCaroline Le Guiner
Jul 31, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Niki C CartyDave Morgan
Mar 9, 2010·CNS & Neurological Disorders Drug Targets·David H Cribbs
Dec 15, 2010·Science·Kwasi G MawuenyegaRandall J Bateman
Jan 5, 2011·Nature Reviews. Neuroscience·Lars M Ittner, Jürgen Götz
Jul 1, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alice ToromanoffCaroline Le Guiner

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
transfection
dot-blot
electrophoresis
Enzyme-Linked ImmunoSorbent Assay
ELISA

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.